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Progress on Pre-pandemic/Pandemic Inﬂuenza Vaccine
M. Tashiro
National Institute of Infectious Diseases, Tokyo, Japan
As pandemic inﬂuenza is a matter of global crisis manage-
ment, WHO has urged to increase international production
and supply of pandemic vaccines. For this, each country
should establish inﬂuenza vaccination policy depending on
annual health burden and economical situation. In Asia,
while only Japan and China produce seasonal inﬂuenza
vaccines, several countries including India, Indonesia, Sin-
gapore, South Korea, Taiwan, Thailand, and Vietnam, are
planning to establish local production of pandemic vaccines.
However, pandemic vaccine policy should be based on sus-
tained annual vaccine measures. WHO started to support
these countries to implement their local vaccine production
of pandemic vaccines. Technical transfer to these facilities
by vaccine manufactures in developed countries is essen-
tial, but it is conﬂicting with business and proﬁts of the
manufactures.
To develop human H5N1 inﬂuenza vaccine, Japan experi-
enced a low immunogenic property in humans of split-type
vaccines derived from A/Hong Kong/156/97(H5N1). The
Japanese project of H5N1 vaccine development aimed to
develop a pandemic vaccine with highly immunogenic and to
spare antigens to provide larger population with the vaccines
in a short period of time. The WHO prototype vaccine strain,
NIBRG-14, propagated in eggs was ﬁxed with formalin. Based
on animal experiments, alum-adjuvanted, inactivated whole
virus vaccines were prepared. Phase 1 clinical studies fol-
lowed by Phase 2+3 studies were conducted with 1.75, 5,
and 15mcg HA/dose in one or two doses, and subcutaneously
or intramuscularly. Results of the clinical studies showed
that the vaccine with 15 mcg HA was tolerable and did not
cause severe adverse event. Serum antibody responses were
induced efﬁciently by one or two shots with the high (15) or
medium dose (5), respectively, of the vaccines, meeting all
of the three EMEA criteria. There results indicated that the
inactivated whole virus vaccine conjugated with alum adju-
vant is a practically suitable formulation of H5N1 pandemic
vaccines. The serum antibody induced by the Clade 1 vaccine
cross-reacted signiﬁcantly with three subclades of Clade 2
viruses.
Based on the data, the Government has introduced
national stockpile policy of prepandemic vaccines, now with
20 million courses. Stockpile is to scale-up annually. Before
expiration of each batch, vaccination to volunteers of the
prioritized groups and then general population is under dis-
cussion.
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uring childhood, the nasopharynx is colonised by a
ariety of bacteria including Streptococcus pneumoniae,
aemophilus inﬂuenzae (mainly non-typable strains - NTHi)
nd Moraxella catarrhalis.1 Generally, nasopharyngeal car-
iage of these bacteria is asymptomatic. However, under
ertain circumstances, bacteria in the nasopharynx may
ause systemic or localised disease. S. pneumoniae is a
eading cause of invasive pneumococcal disease (IPD).1 Elim-
nation of nasopharyngeal pneumococcal colonisation, e.g.
y pneumococcal conjugate vaccines, is strongly associated
ith a reduction in IPD and pneumonia.2
The relationship between nasopharyngeal colonisation
nd otitis media (OM) is more complex. The pathogene-
is of OM involves migration of S. pneumoniae, NTHi or M.
atarrhalis from the nasopharynx to the middle ear. There is
direct relationship between colonisation by pathogens and
he ﬁrst occurrence of acute OM, and colonisation early in
ife by any of the three pathogens is associated with recur-
ent OM.3,4
S. pneumoniae, NTHi and M. catarrhalis are exclu-
ively human pathogens and occupy the same niche, the
asopharynx, along with ∼700 different microbial species.
everal mechanisms are involved in establishing and main-
aining colonisation and in determining the outcome of
ompetition among strains and species. S. pneumoniae and
THi interact synergistically and antagonistically via mech-
nisms that include mediators of innate immunity including
oll-like receptors, bacteriocins, hydrogen peroxide produc-
ion, cell-mediated immunity and complement-dependent
hagocytosis.5—7 A vaccine comprising pneumococcal cap-
ular polysaccharide conjugated to an NTHi surface protein
as efﬁcacy in preventing OM caused by both S. pneumoniae
nd NTHi,8 which provides proof of principle of the feasibil-
ty of preventing OM caused by both bacteria. As vaccines
re developed and tested, surveillance of nasopharyngeal
olonisation will be important because of the critical role
t plays in the pathogenesis of OM, pneumonia and other
espiratory tract infections.
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